09 Feb2015
ECOG-ACRIN Cancer Research Group opens clinical trial for women with newly diagnosed DCIS
In direct response to recommendations made by a National Institutes of Health (NIH) scientific consensus panel, the ECOG-ACRIN Cancer Research Group announced today the opening of E4112, a clinical trial for women with newly diagnosed ductal carcinoma in situ (DCIS) of the breast who, together with their doctors, will use the results of a magnetic resonance imaging (MRI) exam to determine whether to undergo a lumpectomy or a mastectomy. Following that decision, patients and their doctors will use the results of the Oncotype DX® genomic test for DCIS to decide whether to undergo radiation following lumpectomy.
A new drug to treat moderate to severe binge-eating disorder called Vyvanse was recently approved by the US Food and Drug Administration (FDA), the fifth obesity-fighting drug to gain approval in just two years. The move comes on the heels of the FDA’s approval of a first-of-its-kind medical device to fight obesity.